Diabetic Macular Edema – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Diabetic Macular Edema – Pipeline Review, H1 2017’, provides an overview of the Diabetic Macular Edema pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diabetic Macular Edema, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Macular Edema and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Diabetic Macular Edema

The report reviews pipeline therapeutics for Diabetic Macular Edema by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Diabetic Macular Edema therapeutics and enlists all their major and minor projects

The report assesses Diabetic Macular Edema therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Diabetic Macular Edema

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Diabetic Macular Edema

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Diabetic Macular Edema pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Aciont Inc

ActiveSite Pharmaceuticals Inc

Acucela Inc

Aerpio Therapeutics Inc

Allergan Plc

Ampio Pharmaceuticals Inc

Araim Pharmaceuticals Inc

Boehringer Ingelheim GmbH

Cell Medica Ltd

Chengdu Kanghong Pharmaceuticals Group Co Ltd

Chong Kun Dang Pharmaceutical Corp

Clearside BioMedical Inc

Coherus BioSciences Inc

EyeGate Pharmaceuticals Inc

F. Hoffmann-La Roche Ltd

Formycon AG

Genmab A/S

GlaxoSmithKline Plc

Icon Bioscience Inc

Kala Pharmaceuticals Inc

Kalvista Pharmaceuticals Ltd

Kowa Company Ltd

Lupin Ltd

Mabion SA

Oculis ehf

Ohr Pharmaceutical Inc

Oxular Ltd

Pfizer Inc

pSivida Corp

Regeneron Pharmaceuticals Inc

Santen Pharmaceutical Co Ltd

SciFluor Life Sciences LLC

Senju Pharmaceutical Co Ltd

Stealth BioTherapeutics Inc

ThromboGenics NV

Verseon Corp

Xbrane Biopharma AB

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Diabetic Macular Edema - Overview 8

Diabetic Macular Edema - Therapeutics Development 9

Pipeline Overview 9

Pipeline by Companies 10

Pipeline by Universities/Institutes 14

Products under Development by Companies 15

Products under Development by Universities/Institutes 18

Diabetic Macular Edema - Therapeutics Assessment 19

Assessment by Target 19

Assessment by Mechanism of Action 22

Assessment by Route of Administration 26

Assessment by Molecule Type 28

Diabetic Macular Edema - Companies Involved in Therapeutics Development 30

Aciont Inc 30

ActiveSite Pharmaceuticals Inc 30

Acucela Inc 31

Aerpio Therapeutics Inc 31

Allergan Plc 32

Ampio Pharmaceuticals Inc 32

Araim Pharmaceuticals Inc 33

Boehringer Ingelheim GmbH 33

Cell Medica Ltd 34

Chengdu Kanghong Pharmaceuticals Group Co Ltd 34

Chong Kun Dang Pharmaceutical Corp 35

Clearside BioMedical Inc 35

Coherus BioSciences Inc 36

EyeGate Pharmaceuticals Inc 36

F. Hoffmann-La Roche Ltd 37

Formycon AG 37

Genmab A/S 38

GlaxoSmithKline Plc 38

Icon Bioscience Inc 39

Kala Pharmaceuticals Inc 39

Kalvista Pharmaceuticals Ltd 40

Kowa Company Ltd 40

Lupin Ltd 41

Mabion SA 41

Oculis ehf 42

Ohr Pharmaceutical Inc 42

Oxular Ltd 43

Pfizer Inc 43

pSivida Corp 44

Regeneron Pharmaceuticals Inc 44

Santen Pharmaceutical Co Ltd 45

SciFluor Life Sciences LLC 45

Senju Pharmaceutical Co Ltd 46

Stealth BioTherapeutics Inc 46

ThromboGenics NV 47

Verseon Corp 47

Xbrane Biopharma AB 48

Diabetic Macular Edema - Drug Profiles 49

(aflibercept + nesvacumab) - Drug Profile 49

abicipar pegol - Drug Profile 51

ACU-6151 - Drug Profile 55

ACX-107 - Drug Profile 56

aflibercept biosimilar - Drug Profile 57

aflibercept biosimilar - Drug Profile 58

AKB-9778 - Drug Profile 59

ALG-1001 - Drug Profile 63

Antibodies to Inhibit Hemopexin for Diabetic Macular Edema - Drug Profile 67

ARP-1536 - Drug Profile 68

ASPPDC-010 - Drug Profile 69

BI-1026706 - Drug Profile 70

Biologics to Inhibit Semaphorin 3A and VEGF for Diabetic Complications - Drug Profile 72

brolucizumab - Drug Profile 73

bromfenac sodium - Drug Profile 75

cibinetide - Drug Profile 76

conbercept - Drug Profile 79

danazol - Drug Profile 81

darapladib - Drug Profile 85

dexamethasone acetate - Drug Profile 88

dexamethasone acetate - Drug Profile 93

dexamethasone dipropionate XR - Drug Profile 94

dexamethasone palmitate - Drug Profile 95

difluprednate - Drug Profile 96

Drug for Diabetic Macular Edema - Drug Profile 97

EBI-031 - Drug Profile 98

elamipretide - Drug Profile 99

fluocinolone acetonide SR - Drug Profile 107

HO-10 - Drug Profile 116

JDE-006 - Drug Profile 117

KPI-285 - Drug Profile 118

KVD-001 - Drug Profile 119

LKA-651 - Drug Profile 121

loteprednol etabonate - Drug Profile 122

NM-108 - Drug Profile 125

PF-655 - Drug Profile 126

ranibizumab biosimilar - Drug Profile 129

ranibizumab biosimilar - Drug Profile 130

ranibizumab biosimilar - Drug Profile 131

ranibizumab biosimilar - Drug Profile 133

ranibizumab biosimilar - Drug Profile 134

ranibizumab biosimilar - Drug Profile 135

RG-7716 - Drug Profile 136

ripasudil - Drug Profile 138

SF-0166 - Drug Profile 140

Small Molecule for Diabetic Macular Edema - Drug Profile 142

Small Molecule to Inhibit LP-PLA2 for Diabetic Macular Edema - Drug Profile 143

Small Molecules to Inhibit Plasma Kallikrein for Diabetic Macular Edema - Drug Profile 144

squalamine lactate - Drug Profile 145

teprotumumab - Drug Profile 153

TG-931 - Drug Profile 155

THR-149 - Drug Profile 156

THR-317 - Drug Profile 157

triamcinolone acetonide - Drug Profile 160

triamcinolone acetonide - Drug Profile 161

VA-999272 - Drug Profile 167

Diabetic Macular Edema - Dormant Projects 168

Diabetic Macular Edema - Discontinued Products 170

Diabetic Macular Edema - Product Development Milestones 171

Featured News & Press Releases 171

Appendix 183

Methodology 183

Coverage 183

Secondary Research 183

Primary Research 183

Expert Panel Validation 183

Contact Us 183

Disclaimer 184

List of Tables

List of Tables

Number of Products under Development for Diabetic Macular Edema, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Diabetic Macular Edema – Pipeline by Aciont Inc, H1 2017

Diabetic Macular Edema – Pipeline by ActiveSite Pharmaceuticals Inc, H1 2017

Diabetic Macular Edema – Pipeline by Acucela Inc, H1 2017

Diabetic Macular Edema – Pipeline by Aerpio Therapeutics Inc, H1 2017

Diabetic Macular Edema – Pipeline by Allergan Plc, H1 2017

Diabetic Macular Edema – Pipeline by Ampio Pharmaceuticals Inc, H1 2017

Diabetic Macular Edema – Pipeline by Araim Pharmaceuticals Inc, H1 2017

Diabetic Macular Edema – Pipeline by Boehringer Ingelheim GmbH, H1 2017

Diabetic Macular Edema – Pipeline by Cell Medica Ltd, H1 2017

Diabetic Macular Edema – Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, H1 2017

Diabetic Macular Edema – Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2017

Diabetic Macular Edema – Pipeline by Clearside BioMedical Inc, H1 2017

Diabetic Macular Edema – Pipeline by Coherus BioSciences Inc, H1 2017

Diabetic Macular Edema – Pipeline by EyeGate Pharmaceuticals Inc, H1 2017

Diabetic Macular Edema – Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Diabetic Macular Edema – Pipeline by Formycon AG, H1 2017

Diabetic Macular Edema – Pipeline by Genmab A/S, H1 2017

Diabetic Macular Edema – Pipeline by GlaxoSmithKline Plc, H1 2017

Diabetic Macular Edema – Pipeline by Icon Bioscience Inc, H1 2017

Diabetic Macular Edema – Pipeline by Kala Pharmaceuticals Inc, H1 2017

Diabetic Macular Edema – Pipeline by Kalvista Pharmaceuticals Ltd, H1 2017

Diabetic Macular Edema – Pipeline by Kowa Company Ltd, H1 2017

Diabetic Macular Edema – Pipeline by Lupin Ltd, H1 2017

Diabetic Macular Edema – Pipeline by Mabion SA, H1 2017

Diabetic Macular Edema – Pipeline by Oculis ehf, H1 2017

Diabetic Macular Edema – Pipeline by Ohr Pharmaceutical Inc, H1 2017

Diabetic Macular Edema – Pipeline by Oxular Ltd, H1 2017

Diabetic Macular Edema – Pipeline by Pfizer Inc, H1 2017

Diabetic Macular Edema – Pipeline by pSivida Corp, H1 2017

Diabetic Macular Edema – Pipeline by Regeneron Pharmaceuticals Inc, H1 2017

Diabetic Macular Edema – Pipeline by Santen Pharmaceutical Co Ltd, H1 2017

Diabetic Macular Edema – Pipeline by SciFluor Life Sciences LLC, H1 2017

Diabetic Macular Edema – Pipeline by Senju Pharmaceutical Co Ltd, H1 2017

Diabetic Macular Edema – Pipeline by Stealth BioTherapeutics Inc, H1 2017

Diabetic Macular Edema – Pipeline by ThromboGenics NV, H1 2017

Diabetic Macular Edema – Pipeline by Verseon Corp, H1 2017

Diabetic Macular Edema – Pipeline by Xbrane Biopharma AB, H1 2017

Diabetic Macular Edema – Dormant Projects, H1 2017

Diabetic Macular Edema – Dormant Projects, H1 2017 (Contd..1), H1 2017

Diabetic Macular Edema – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Diabetic Macular Edema, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports